{"name":"Cogent Biosciences, Inc.","slug":"cogent-biosciences-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"CGT9486","genericName":"CGT9486","slug":"cgt9486","indication":"Acute myeloid leukemia (AML) with FLT3 mutations","status":"phase_3"},{"name":"CGT9486 plus sunitinib","genericName":"CGT9486 plus sunitinib","slug":"cgt9486-plus-sunitinib","indication":"Acute myeloid leukemia with FLT3 mutations","status":"phase_3"}]}],"pipeline":[{"name":"CGT9486","genericName":"CGT9486","slug":"cgt9486","phase":"phase_3","mechanism":"CGT9486 is a selective tyrosine kinase inhibitor that targets FLT3, a receptor implicated in acute myeloid leukemia and other hematologic malignancies.","indications":["Acute myeloid leukemia (AML) with FLT3 mutations"],"catalyst":""},{"name":"CGT9486 plus sunitinib","genericName":"CGT9486 plus sunitinib","slug":"cgt9486-plus-sunitinib","phase":"phase_3","mechanism":"CGT9486 is a selective FLT3 inhibitor combined with sunitinib, a multi-targeted tyrosine kinase inhibitor, to block FLT3 and PDGFR signaling in acute myeloid leukemia.","indications":["Acute myeloid leukemia with FLT3 mutations"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxNZFZ3cEFnaUlnSGp3TzZIQXNibTVZajhPclJaX20ydUpJcUdGSlY2MUw0OXVIbXo2ME9abURXenF1WmoxdnNhbWhYYUk0SXA1VXVwS0x2TzlBVnR0UmlYX1h2QzZoR1FZckdSNHhYTE80cGo1ekVQdlVYdk1MSjVHZzdFUnVHbml6VElJd1BoTUxLY1RkZGdXRnM4QS1hc0F0R1Bwa0dhcXMxNUdTYkhWTmJwUTJuMS1yOUNxR2VXbWxwNkFMalBUMU5qZTRGS0x3RFZfNHFMajM0OThpZ3NLUE5DdHZ3ZHBxT0RR?oc=5","date":"2026-03-30","type":"pipeline","source":"Proactive financial news","summary":"Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts - Proactive financial news","headline":"Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQNUZoX0ljWVc2eERmUHc4T2dCNUxaSlBObE9mTU1ZVnNhWUhZWXc1Y0hXYUdQRWJ6Z2dyZi1xbGFzdmk5dHdDdVBKSDh0dWM2Q2FnNk5nQkd4RlpKU3BLamZKQVoyVFp2d09LVW54aGF5blpyamRwY3FmSWlMNjBOV0tmRlJPc1lfbnpBQmhLVWNSQWZjQWNzUzFiN1d6SGNPNGlhcE5PdFJTOUN4NjhIOHR0cGwwYkY1ZkdRN2lQLUNpa3lpdU13WEpuVjhxSGNaazFiNkFXLVhHaFlVSEE?oc=5","date":"2026-03-17","type":"regulatory","source":"The Globe and Mail","summary":"COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM - The Globe and Mail","headline":"COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPT0dYRzJzX0tnWUQ4U3F3TjR6UHFaVFBTVTZqUlFiMkZ2UjliLTh3WnJjX2IyZ3V2YjlWYld6RjRTUWZoZS1UbDlhRHlPS2lHMlREZXg0LTBuVlBIQ2QtUDREb0J0ZjZYdHpyWEk3LW1oUGFFTGZJVXhYN1RRbDJVWldScWM5ZGZjdmZseVoyOWFEU0RYWjhuQ1FxOVRPSmtjNGwtYm0tYTRmSTRpQ3hELU9R?oc=5","date":"2026-03-04","type":"regulatory","source":"Seeking Alpha","summary":"Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish (NASDAQ:COGT) - Seeking Alpha","headline":"Cogent Biosciences: Trio Of Approvals Beckon For Lead Drug - Still Bullish (NASDAQ:COGT)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wJBVV95cUxQNXVJTlhfWUNuUnBBTWcwOTZyMzQ2LXk3eEVmczdZZWxlOWdVQllaY3VSZV84RjhSRTF4czlRM2tPMllVR2F2TkNPb0w3QW9hNXhUY0N0bzQwaWVGUUtwVUk1R3pJNnB6MVp3dGs4aC1PYW51YlZ3TTl6MVJmcEpmMGxDRjNqczk4b2oyMjJIcWZRQTBfVVlMelBvTERFcU1XdzB1bDJmVlMxOWgyWGdJdmt5NEI4Nldmcml1M2drdS13aVdubzZ1Rm8yWkxjWmU1YXZwN1hZNXlUQ1VYZGxQbkUxVThqd21hYjVlMi1qN1lBR05COVlxUnlUSnktdEN1QlBrWS01Y2duaHBLVXdIdzNodUNRMFNacUhsNHZpZHBLZm1zb3F6cEtwWmlOVTBfMVRmNGVCbE9ObkxpQVJ1MVpaTXVDVGpxelpGckNEb3VzV3BPeEo4?oc=5","date":"2026-01-26","type":"pipeline","source":"globenewswire.com","summary":"Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) - globenewswire.com","headline":"Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patien","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQVDZqSktsbFVJMDZSS2xKY3hFSnZTVW5ZQTFlN2FyczBPalBFZFlEWGg4a3paMmg3Y0lfaGJkVmR1amV6b0p2cUtLamd6ek8xRG0wUkhFbkZEclJfNXcza0VUdm03QXEza1V2eDdMTE13NnB5OG5qUEdJVk9BYzNZV1ZXWEU5LUlNandpbFo1QndER2J4NDhOV3hn?oc=5","date":"2026-01-02","type":"pipeline","source":"Barron's","summary":"Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barron's","headline":"Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxPekZla291cnhfTUtFLXRGYmV4VXBEakZ5SGo1aDFPbGJuaGh2YWRKaW9FSjljS29yYWlsZTd6ZGt4NWJiWXlENEpSOGlCWEJpU2d2WWRfc0cxMmt4WVlVYVBnNHJ3MUc3TFpHc19idHhpb1E5ejgzRmg4NzlWcF9QcW0zNVppTXZ0bVlNSHBjRHljR1JPNUdDMnFzM2NfVlNPR3ZoaXoyMWN2XzhwcElvZFZJallDM2xCaHJtQ2RwcFpmWE9mNEZmclkwS0dHMW5velkwS3RsNmp3cnRrN1hvNU9rYTB1cW9LbUNrUlhReWNZbGlxaW9LbFBaT1ViYVpSbGFyREtTZXVyR3Z2UHVqYmZsU3lLWnR1QVR4LU0wN1dmVVAzTFE?oc=5","date":"2025-11-11","type":"pipeline","source":"globenewswire.com","summary":"Cogent Biosciences Announces Pricing of Concurrent Public - globenewswire.com","headline":"Cogent Biosciences Announces Pricing of Concurrent Public","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOMUhiYXB3V0xpRHdHM01ObkJVMndZTDVPYTlXUjAzUUc0NFZHRGJoVjBxOWJVRTd6eVdhTDE1YUZqSV92dUFfVnJVS1lpalQyNkh5MjJFN3QtOXRfOGxEdnlMUjU3blh0a0pqeHVBY05fdTdSeE83amd0Q3NIMXAwUWVVUlNsb1NzZFBNYXpWYzdUYXh1cGFTMzVNb0MtaVVDZXJCelJHZkhxOVJ3SEE?oc=5","date":"2025-11-11","type":"trial","source":"Seeking Alpha","summary":"Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT) - Seeking Alpha","headline":"Cogent Biosciences: Soaring On Blowout GIST Data - I Expect More Upside (NASDAQ:COGT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPcXlRcDlnMHJoM2N2NUNORWRRMXFYVEZYZzYtQWRQdEROVzJyTEFPWDlNSmJoNjFmYVhRNFF4emFDdzdIOS04QU5qWjB2MTJ6TExMaFZTUmJ2TjZoTUNaaHZFcVJfQ1hwYVViX0lnT1IwYktSS2Jjb3ZsTE1Sd1R2TmFLMklsb3p6?oc=5","date":"2025-11-10","type":"pipeline","source":"Barron's","summary":"Cogent Biosciences Stock Surges 136%. Why Investors See Promise in Its Cancer Drug. - Barron's","headline":"Cogent Biosciences Stock Surges 136%. Why Investors See Promise in Its Cancer Drug. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPa2UySDNiNlI2YUJVektia0VoYmViZno5OF95dFh4NWtjdXZMZ3paM3BiOTl6dGpZOHY3QldnVnBZYVZvRVgxZzlWc2lhSFpjc2xhMWNLdm9lVnZieS0zbWNNUjJ6eERRYlV6OEdQaWpTS3d5MmV5R0FCYmxyZEJzUTNsMjVkRlpJX1FlNndRT1lOLVRIczY4U1RWYTVzR09Wb0VTUDNNeUF2enljSnhxMk9RRU5jUQ?oc=5","date":"2025-11-10","type":"regulatory","source":"Fierce Biotech","summary":"Cogent eyes FDA submission for cancer asset after clearing another phase 3 hurdle - Fierce Biotech","headline":"Cogent eyes FDA submission for cancer asset after clearing another phase 3 hurdle","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNS0x3VjBYMFRaNjNIYWFZSXJvQnh0WXhENTlhNnkwVDJZX21qOFR4WDg3TFFSbG1rWjF3XzBFTjJQcS03eVF3UTJMQnVHNFdXeUVXTlEwZ0oxNTRMUXk3T2VROXJrSWxYOFZ0czRwN2VDOHV6akU4Q1BDU2pJVVBUXzBhLXZmZlB0Ym9CelI0WnctWkQtWUdjc3NCbTJKa1AyYmlsQ1c3b1F0RGZxY09yaGhzT2FSTDI5VFl0dkFmQ0MzS3hRaHJYdjdPLTE3RjFjdVFyVEdGNTF5YnBaSWk3M0JjVEJobzJKUHN0WDVTZ0l1bFZjTHAtLVhUd3JNUnAtMVgzWjdEdUwydzFjZjdpVkZZZjNIVVZUVmx1WTIxR0hpZw?oc=5","date":"2025-11-10","type":"earnings","source":"Benzinga","summary":"Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Bi - Benzinga","headline":"Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Bi","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE9mdlBUNDVhWTBhVXAybUlqNW9xQ0VFYVdjdDJwdjluX2FsS25wWHUxWHhSZGhkSTlTMlRoVFFFNHFfYm93V1E4R09GTFJwa2pjbGRTb0hWOFBBcFdIMHdZRDdER3hnMU1pTi1saHZlVm1iM0habVkyVU9Jd1c?oc=5","date":"2025-07-08","type":"trial","source":"Yahoo Finance","summary":"COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - Yahoo Finance","headline":"COGT Stock Soars on Phase III Systemic Mastocytosis Study Success","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQVFA5eDFLcnNfQ3Q4WGdfMGFLcXJiUmxpTTEwYy1yY0Q2M1NRTER2RXFWeDRuYk5qMkxhcFJXdTNHcWhJMFFlTkR3WjZTNVFxcDF4LUltTGZuSXRSaXFQa05hcTVDVEdKV1EwOW55dm53VE1PQlFydWNHdlFMRFg5Sy1tRDNOTjNzOUlqelNCa0J2b1BKMndidEctWVhCdmRi?oc=5","date":"2025-07-07","type":"trial","source":"BioPharma Dive","summary":"Study results boost Cogent’s case for rare disease drug - BioPharma Dive","headline":"Study results boost Cogent’s case for rare disease drug","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}